Announcements Trials

Browse Landscape

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1522 Carcinoma, Non-Small-Cell Lung 758 Breast Neoplasms 572 Neoplasm Metastasis 531 Colorectal Neoplasms 448 Melanoma 390 Leukemia, Myeloid, Acute 371 Multiple Myeloma 364 Ovarian Neoplasms 354 Recurrence 336 Lymphoma 334 Advanced Solid Tumors 326 Lymphoma, Non-Hodgkin 315 Prostatic Neoplasms 302 Pancreatic Neoplasms 285 Advanced Solid Tumor 240 Stomach Neoplasms 234 Carcinoma, Renal Cell 226 Squamous Cell Carcinoma of Head and Neck 211 Lung Neoplasms 211 Solid Tumor 204 Leukemia, Lymphocytic, Chronic, B-Cell 198 Triple Negative Breast Neoplasms 185 Solid Tumors 183 Carcinoma, Hepatocellular 165 Hematologic Neoplasms 155 Head and Neck Neoplasms 153 Lymphoma, Large B-Cell, Diffuse 148 Lymphoma, Follicular 146 Glioblastoma 145

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × INDUSTRY × Safety Issues × Clear all

NCT05580172 2022-10-17

Phase 1 Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer

ReHeva Biosciences,Inc.

Phase 1 Unknown

Safety Issues

Data powered by HemOnc (CC BY 4.0) Colophon ⚡